Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tutt

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast CancerMelek Akay, Jennifer Glendenning, Holly Tovey, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2023
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)Holly Tovey, Orsolya Sipos, Joel S Parker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2022
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast CancersPatrycja Gazinska, Charlotte Milton, Jacopo Iacovacci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
Cell Reports|May 16, 2019
Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast CancerRachel Evans, Fabian Flores-Borja, Sina Nassiri, et al.
BMC Cancer|November 26, 2008
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signatureAndrew Tutt, Alice Wang, Charles Rowland, et al.
Molecular Cancer Therapeutics|November 15, 2017
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast CancerKalnisha Naidoo, Patty T Wai, Sarah L Maguire, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast CancerMelek Akay, Jennifer Glendenning, Holly Tovey, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2023
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)Holly Tovey, Orsolya Sipos, Joel S Parker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2022
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast CancersPatrycja Gazinska, Charlotte Milton, Jacopo Iacovacci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
Cell Reports|May 16, 2019
Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast CancerRachel Evans, Fabian Flores-Borja, Sina Nassiri, et al.
BMC Cancer|November 26, 2008
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signatureAndrew Tutt, Alice Wang, Charles Rowland, et al.
Molecular Cancer Therapeutics|November 15, 2017
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast CancerKalnisha Naidoo, Patty T Wai, Sarah L Maguire, et al.
Pageof 10